We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App


15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024
25 Apr 2024 - 27 Apr 2024

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

By LabMedica International staff writers
Posted on 02 Jun 2023
Print article
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising sample preparation, incubation, washing, and mounting of slides as well as image acquisition and analysis.

EUROIMMUN (Lübeck, Germany) has introduced the UNIQO 160 (CE-IVDR automated IIFT system, a unique benchtop device that combines a fully automated processing system with a high-quality microscope and can be seamlessly integrated into existing diagnostics laboratory workflows. The device boasts the capability to process 160 primary samples and 18 slides per run, while automatically identifying individual samples, reagents, and slides using barcode recognition. This ensures a high level of reliability and traceability of both materials and samples. Additionally, the UNIQO 160 applies a mounting medium and a cover glass for incubated slides to prevent them from drying out, which is a crucial step for achieving high-quality fluorescence images.

The UNIQO 160 generates brilliant fluorescence images using its optical system's autofocus feature and three automatically interchangeable objectives (4x, 10x, 20x). The captured images are then relayed to the system's EUROLabOffice 4.0 middleware for evaluation. Ideal for medium-throughput laboratories, the UNIQO 160 is the latest addition to EUROIMMUN's range of automated laboratory solutions, joining the likes of the EUROPattern Microscope Live, EUROLabWorkstation IFA, and Sprinter XL systems. The UNIQO 160 is also expected to be compatible with the forthcoming EUROPattern Classifier, a software platform that employs cutting-edge pattern classification using artificial intelligence to assist in the final evaluation and suggest analytical results.

“Traditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,” said Dr. Bianca Huth, chief technology officer of EUROIMMUN. “The design of the UNIQO 160 system and technologies built into it alleviate laboratories of many common challenges by reducing hands-on time and creating efficiencies through end-to-end automation.”

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Real-time PCR System
GentierX3 Series

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.